Compare HCC & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HCC | XGN |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 140.3M |
| IPO Year | 2017 | 2019 |
| Metric | HCC | XGN |
|---|---|---|
| Price | $89.10 | $6.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $74.50 | $13.67 |
| AVG Volume (30 Days) | ★ 715.6K | 258.8K |
| Earning Date | 02-12-2026 | 11-04-2025 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.67 | N/A |
| Revenue | ★ $1,224,320,000.00 | $63,599,000.00 |
| Revenue This Year | N/A | $21.76 |
| Revenue Next Year | $47.09 | $15.63 |
| P/E Ratio | $133.32 | ★ N/A |
| Revenue Growth | N/A | ★ 14.08 |
| 52 Week Low | $38.00 | $2.67 |
| 52 Week High | $89.90 | $12.23 |
| Indicator | HCC | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 70.08 | 24.89 |
| Support Level | $78.00 | $5.93 |
| Resistance Level | $89.90 | $6.80 |
| Average True Range (ATR) | 3.12 | 0.35 |
| MACD | 0.32 | 0.03 |
| Stochastic Oscillator | 92.31 | 9.47 |
Warrior Met Coal Inc is a U.S based company. It produces and exports of met coal that operates underground mines in Alabama. The company sells to steels manufacturers in Europe, Asia, and South America. Its mining operations consist of two underground met coal mines in Southern Appalachia's coal seam and other surface met and thermal coal mines. The Company generates ancillary revenues from the sale of natural gas extracted as a byproduct from the underground coal mines and royalty revenues from leased properties.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.